Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myeloma Drug Access Limits Unlikely Near-term – Aetna, Express Scripts Say

This article was originally published in The Pink Sheet Daily

Executive Summary

ICER’s cost-effectiveness assessment won't lead to place step therapy restrictions on sequence of multiple myeloma treatment regimens – at least until there's better data.

Advertisement

Related Content

Ovarian Cancer Drugs Will Get ICER Review As Olaparib's Maintenance Indication Looms
Multiple Myeloma Would Make Good Guinea Pig For Oncology Cost Control

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079463

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel